Skip to content Skip to footer

Halozyme Therapeutics to Acquire Elektrofi for ~$900M, Expanding its Drug Delivery Offerings

Shots:Halozyme Therapeutics has entered into a definitive agreement to acquire Elektrofi, incl. its Hypercon technology, which enables biologic formulations at concentrations of 400-500mg/mlAs per the deal, Elektrofi will receive $750M upfront, with up to three $50M milestone payments contingent on regulatory approvals of three separate Hypercon products; closing expected in Q4’25As a result…

Read more

Post Conference Highlights: Peptides & Complex Generics Symposium 2025

Day 1 BreakdownThe #PCG2025 Symposium commenced on an inspiring note, setting the stage for two days of insightful discussions, collaborations, and knowledge exchange.Opening SessionDr. Ratnesh Jain, Founder & Director, Mumbai Cluster, delivered the inaugural address, sharing his vision of bringing together pharma professionals, R&D experts, CXOs, and academicians to accelerate advancements in…

Read more

VIEWPOINTS_Patrick Mooney_2024

Intraocular Drug Delivery: Patrick Mooney from SpyGlass Pharma in Conversation with PharmaShots

Shots: Out of the 5M cataract procedures in the US, around one-fifth are conducted on patients with glaucoma or ocular hypertension. There’s an unmet need for drug delivery for patients who struggle with topical drops Today, with PharmaShots, CEO of SpyGlass Pharma, Patrick Mooney, sharing insights from the data presented at the ASCRS Annual Meeting Patrick…

Read more